Drug Trial Radar · NCT01766206
Safety of One Dose of Meningococcal ACWY Conjugate Vaccine in Subjects From 2 Months to 55 Years of Age in the Republic of South Korea
Last checked: Nov 19, 2026Latest source record: Sep 21, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
3,948
Actual
Start
Mar 15, 2013
Primary completion
Jan 22, 2018
Study completion Jan 22, 2018
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Jan 11, 2013
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 2 months, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
A multicenter, single arm, post-marketing surveillance study. This study is a postlicensure requirement of the Korea Food and Drug Administration (KFDA) to provide continued safety evaluation of MenACWY in the Korean population from 2 months to 55 years of age, receiving MenACWY-CRM vaccination according to routine clinical practice and prescribing information.
Conditions
- Meningococcal Disease
Interventions
MenACWY-CRM (Menveo)Biological
One dose administered intramuscularly preferably into the anterolateral aspect of the thigh in infants or into the deltoid muscle in children, adolescents and adults.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Subjects Reporting Any Local and Systemic Solicited Adverse Events (AEs)Time frame: From Day 1 of vaccination to Day 7 post vaccination
- Number of Subjects Reporting Any Unsolicited Adverse Events (AEs)Time frame: From Day 1 of vaccination to Day 7 post vaccination
- Number of Subjects Reporting Medically Attended AEs (MAAEs)Time frame: From Day 1 of vaccination to study termination (Day 29/early termination)
- Number of Subjects Reporting Serious AEs (SAEs)Time frame: From Day 1 of vaccination to study termination (Day 29/early termination)
Locations
54 sites in 1 country. Site status is shown where the registry gives one.
GSK Investigational Site
Ansan, South Korea
GSK Investigational Site
Anyang, South Korea
GSK Investigational Site
Bucheon-si, South Korea
GSK Investigational Site
Busan, South Korea
GSK Investigational Site
Changwon, South Korea
GSK Investigational Site
Daegu, South Korea
GSK Investigational Site
Daejeon, South Korea
GSK Investigational Site
Daejeon, South Korea
GSK Investigational Site
Donghae, South Korea
GSK Investigational Site
Gimhae, South Korea
GSK Investigational Site
Goyang-si, South Korea
GSK Investigational Site
Goyang-si, Gyeonggi-do, South Korea
GSK Investigational Site
Guro Gu, South Korea
GSK Investigational Site
Gwangmyeong, South Korea
GSK Investigational Site
Gwangmyeong, South Korea
GSK Investigational Site
Gyeonggi-do, South Korea
GSK Investigational Site
Gyeonggi-do, South Korea
GSK Investigational Site
Gyeonggi-do, South Korea
GSK Investigational Site
Gyeonggi-do, South Korea
GSK Investigational Site
Incheon, South Korea
GSK Investigational Site
Incheon, South Korea
GSK Investigational Site
Incheon, South Korea
GSK Investigational Site
Jeju City, South Korea
GSK Investigational Site
Jeollanam Do, South Korea
GSK Investigational Site
Kyeonggido, South Korea
GSK Investigational Site
Pyeongtaek-si, South Korea
GSK Investigational Site
Seoul, South Korea
GSK Investigational Site
Seoul, South Korea
GSK Investigational Site
Seoul, South Korea
GSK Investigational Site
Seoul, South Korea
GSK Investigational Site
Seoul, South Korea
GSK Investigational Site
Seoul, South Korea
GSK Investigational Site
Seoul, South Korea
GSK Investigational Site
Seoul, South Korea
GSK Investigational Site
Seoul, South Korea
GSK Investigational Site
Seoul, South Korea
GSK Investigational Site
Seoul, South Korea
GSK Investigational Site
Seoul, South Korea
GSK Investigational Site
Seoul, South Korea
GSK Investigational Site
Seoul, South Korea
Showing 40 of 54 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.